A Prospective Longitudinal Collection of Subjects Diagnosed With Small Cell Lung Cancer

Terminated

• Conditions: Small Cell Lung Cancer

• Registration Number: NCT01591512
• Lead Sponsor: Fujirebio Diagnostics, Inc.

Brief Summary

The purpose of this study is to collect samples to evaluate the ProGRP and NSE assays independently as aids for monitoring the course of disease and therapy in subjects diagnosed with SCLC.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-05
• Study First Submitted: 2012-05-02
• Study First Submitted QC: 2012-05-03
• Study First Posted: 2012-05-04
• Primary Completion: 2012-07
• Study Completion: 2012-07
• Status Verified: 2015-03
• Last Update Submitted: 2015-03-04
• Last Update Posted: 2015-03-06

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 4

Inclusion Criteria

• Age ≥ 18
• Confirmed diagnosis of SCLC or mixed SCLC/non-SCLC per histopathology results
• Scheduled to undergo first-, second- or third-line treatment for SCLC, including chemotherapy, chemotherapy + radiation therapy, or combined concurrent chemoradiotherapy.
• Able to understand and willing to provide Informed Consent

Exclusion Criteria

• No diagnosis of SCLC
• Not scheduled to undergo treatment for the diagnosis of SCLC
• Unable to provide Informed Consent

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (4)

Hematology Oncology Consultants, Inc.; 🇺🇸 St. Louis, Missouri, United States

Kelly Family Medical Center, PC; 🇺🇸 Eastpointe, Michigan, United States

Heartland Regional Medical Center; 🇺🇸 St. Joseph, Missouri, United States

St.Louis Cancer Care, LLP; 🇺🇸 Bridgeton, Missouri, United States